Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 10, 2014, details the results of Ultragenyx Pharmaceutical Inc.'s Annual Meeting of Stockholders held virtually on that date. The record date for the meeting was May 16, 2014, with 30,059,288 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on four proposals, all of which were approved:
- Proposal 1 (Election of Directors): Emil D. Kakkis, M.D., Ph.D., was elected as a Class I Director. He received 18,589,833 votes for, with 2,836,852 votes withheld and 684,420 broker non-votes.
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2014. Votes were 22,107,166 for, 3,385 against, and 554 abstentions.
- Proposal 3 (2014 Incentive Plan): Stockholders reapproved the Internal Revenue Code Section 162(m) provisions of the 2014 Incentive Plan. Votes were 17,129,073 for, 4,296,022 against, 1,590 abstentions, and 684,420 broker non-votes.
- Proposal 4 (Corporate Bonus Plan): Stockholders reapproved the Internal Revenue Code Section 162(m) provisions of the Corporate Bonus Plan. Votes were 21,406,334 for, 18,761 against, 1,590 abstentions, and 684,420 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Confirmation that Emil D. Kakkis, M.D., Ph.D., serves on the Board of Directors until the 2017 Annual Meeting.
- Verification that Ernst & Young LLP is the appointed auditor for the fiscal year ending December 31, 2014.
- Review of the 2014 Incentive Plan and Corporate Bonus Plan to understand the approved Section 162(m) provisions.
- Analysis of the significant number of votes withheld or cast against the Incentive Plan (Proposal 3) compared to other proposals.